報價延遲最少15分鐘:2025/07/21 16:38 EDT
盤後時段
|
||||
|
1.67 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.29/-0.50
|
|
企業價值
9.93M
|
| 資產負債 |
|
每股賬面淨值
1.18
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
4.90M
|
|
每股收益
0.21
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/21 16:38 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products. |
